A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor Progression
NCT01604512 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 148
Last updated 2025-04-08
Summary
This study will examine if MRI perfusion and PET/CT can tell growing tumor and radiation injury apart. MRI perfusion looks at the blood vessels in the tumor. PET/CT looks if the tumor cells are actively growing. The investigators will do these two tests and see which one is better.
Patients will remain on study until the completion of either the MRI perfusion or PET/CT that are within 12 weeks of each other. After one of these scans, the patient will have no active interventions and will be off study.
Optional: Restriction Spectrum Imaging (RSI) Sequence RSI sequence is an advanced way of looking at your brain. The scan allows doctors to see how water is moving within brain tumors or within brain cells. The extra sequence takes additional 4-5 minutes in the scanner. The RSI sequence is optional. The patient will only be asked to participate if the doctor believes that it will be helpful.
Off study: Patients will remain on study until the completion of either the MRI perfusion or PET/CT that are within 12 weeks of each other. After one of these scans, the patient will have no active interventions and will be off study. Patients will obtain a standard of care brain MRI scan about every 2-3 months. These MRI scans will be used to track disease progression.
Conditions
Interventions
- DIAGNOSTIC_TEST
-
MRI perfusion and PET/CT scans
The MRI perfusion and PET/CT scans will be obtained within 12 weeks of each other. These scans are part of the standard of care for patients with brain tumors and uncertain tumor response or progression after treatment. Although every effort will be made to perform both MRI perfusion and PET/CT on the same day or during the same week, some patients may experience longer intervals between scans due to scheduling conflicts. The disease in question (radiation injury vs. tumor progression) may change slightly during this interval (e.g., the lesion may grow or shrink slightly), but no large changes are expected between the two scans. The patients may continue existing treatments in the interval between scans (e.g., steroids, chemotherapy), but the two scans must be performed before any change or new treatment occurs. Fusion images of MRI and PET/CT will not be reviewed by the neuroradiologist interpreting the MRI perfusion nor the nuclear medicine radiologist interpreting the PET/CT.
Sponsors & Collaborators
-
Memorial Sloan Kettering Cancer Center
lead OTHER
Principal Investigators
-
Robert Young, MD · Memorial Sloan Kettering Cancer Center
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-05-31
- Primary Completion
- 2023-12-29
- Completion
- 2023-12-29
Countries
- United States
Study Locations
More Related Trials
-
PET and MRI Imaging of Brain Tumors Using [18F]PARPi
NCT04173104 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Brain Imaging Biomarkers in Patients With Brain Metastasis
NCT04197297 ·Status: RECRUITING ·Phase: PHASE2
-
Radionecrosis and FDG PET
NCT02391246 ·Status: UNKNOWN
-
PET and MRI in the Follow-up of Neoadjuvant Chemotherapy of Breast Cancer
NCT00236275 ·Status: COMPLETED ·Phase: PHASE3
-
Utility of Perfusion MRI to Detect Radiation Necrosis in Patients With Brain Metastases
NCT03680144 ·Status: COMPLETED ·Phase: NA
-
A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
NCT06145399 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1
NCT00968656 ·Status: COMPLETED ·Phase: PHASE1
-
Initial Assessment of 18FDG-PET/MRIin Determining the Extent of Systemic Disease in Breast Cancer Patients
NCT01672021 ·Status: COMPLETED ·Phase: NA
-
Comparison Study Between PET/CT and Whole-Body Diffusion Weighted MRI in the Detection of Distant Malignancies
NCT06205901 ·Status: NOT_YET_RECRUITING
-
PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy
NCT00019565 ·Status: COMPLETED ·Phase: PHASE1
-
Integrated PET/MR Imaging With Amino Acid Radiotracers in the Evaluation of Brain Neoplasms: Assessing Diagnostic Accuracy and Therapeutic Response
NCT07211360 ·Status: NOT_YET_RECRUITING
-
Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals
NCT03125629 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Brain Metastases Treated With Stereotactic Radiotherapy Using Dynamic [18F]FDG PET
NCT06511323 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning
NCT03286972 ·Status: TERMINATED
-
Comparaison Between MRI Alone or Combined With Positron Emission Tomography for Brain Metastasis Diagnosis
NCT05095766 ·Status: COMPLETED
-
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
NCT01806675 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Non Invasive Methods for Differential Diagnosis Radionecrosis/Recurrence After Radiosurgery of Brain Metastases
NCT02636634 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Metabolic Agents Following Brain Radiation
NCT06150547 ·Status: COMPLETED
-
PET/MRI Perfusion and CT Perfusion in Solid Tumors
NCT02314962 ·Status: TERMINATED
-
A Study of Radiation Toxicity in the Liver Using MRI-Based Perfusion
NCT01210027 ·Status: COMPLETED
-
Dynamic F-DOPA PET for Differential Diagnosis Between Recurrence and Radionecrosis of Brain Metastasis
NCT05762172 ·Status: COMPLETED ·Phase: NA
-
68Ga-NOTA-NFB: Radiation Dosimetry in Healthy Volunteers and Applications in Glioma Patients or Breast Cancer Patients
NCT02327442 ·Status: UNKNOWN
-
Dual Integrin αvβ3 and GRPR Targeting PET Imaging in Breast Cancer Patients
NCT02749019 ·Status: UNKNOWN ·Phase: PHASE1
-
[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
NCT06502691 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Proton MR Spectroscopy of Brain Metastases in Evaluation of Treatment Response.
NCT00184288 ·Status: WITHDRAWN